News and Press Releases
Aptamer Group Introduces Novel Biomarker Discovery Service
Accelerated platform delivers validated biomarkers with ready-to-use Optimer ligands in months rather than years Biomarkers are identified based on their ability to translate to drug development strategies. 28 August 2025...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: August 28, 2025
Aptamer group, Suite 2.80 – 2.87, Bio Centre, Innovation Way, Heslington, York, YO10 5NY
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer’s Patient Treated with Intranasal Foralumab
9 May 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3...
Category: Biotechnology, Other, Pharmaceutical
Posted: May 9, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial
Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries Safety and functionality data for the updated Liquid Biopsy System supports continuation of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Leqembi ▼ (lecanemab) proposed Marketing Authorisation Variation for monthly intravenous maintenance dosing for the treatment of early Alzheimer’s disease in the UK is validated for evaluation by the MHRA
Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment The...
Category: Other, Pharmaceutical
Posted: April 30, 2025
Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorised in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2025
Groundbreaking health research gets £7.6m boost as Academy of Medical Sciences funds emerging scientific leaders
7 April 2025 -- London, UK -- In its largest-ever funding initiative for early-career researchers, the Academy of Medical Sciences is investing £7.6 million to tackle urgent health challenges from...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
OGT delivers superior MRD detection capabilities with new SureSeq Myeloid MRD Panel
22 January 2025 – New York City, NY, US – Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq™ Myeloid MRD Panel, which provides a...
Category: BioManufacturing
Posted: January 23, 2025
Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, UK
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
9 January 2025 -- Cambridge, UK and Montreal, Canada -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 9, 2025
Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors
Mr. Satter’s Extensive Investment, Company-Building, and Transaction Experience Strengthens Alzheon’s Board Leadership Valiltramiprosate/ALZ-801 Has Potential to Become the First Oral Agent to Slow Alzheimer’s Pathology in Patients APOLLOE4 Pivotal Phase...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 7, 2025
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
17 December 2024 -- New York, US -- Tiziana Life Sciences, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: December 17, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
DNA analysis of Parsortix-enriched CTCs and ctDNA provides complementary information in NSCLC patients treated with AstraZeneca’s osimertinib
The addition of CTC-DNA analysis to clinical trials could identify patients developing treatment resistance prior to disease progression CTC analysis identifies druggable targets which could be used to inform combined...
Category: Biotechnology, Clinical Trials
Posted: November 11, 2024
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
19 September 2024 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: September 19, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD FDA Fast Track...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 17, 2024
MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test
11 September 2024 -- Cambridge, UK -- MicrosensDx is excited to announce that it is working with The Mayr Group at Imperial College London to develop a novel biomarker test...
Category: Biotechnology, Other
Posted: September 11, 2024
osteolabs Publishes First Real-World Evidence Data from Close to 3,000 OsteoTest Patient Samples
First report on the application of CIM (Calcium isotope marker) technology in serum and urine demonstrating excellent correlation of CIM with all metabolic diseases, therapies, and diets affecting musculoskeletal metabolism...
Category: Biotechnology, Other, Pharmaceutical
Posted: August 15, 2024
